Solid Biosciences Inc.
SLDBNASDAQHealthcare● Active
$6.41
$-0.29(-4.33%)
Market Cap$499404382
P/E Ratio—
52W High$8.866
52W Low$3.79
Solid Biosciences Inc. (SLDB) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SLDB · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.17B) | ($0.12B) | ($0.10B) | ($0.09B) | ($0.07B) |
| Depreciation & Amort. | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.02B | $0.01B | $0.01B | $0.01B | $0.01B |
| Change in Working Capital | ($0.01B) | $0.00B | ($0.01B) | ($0.00B) | ($0.02B) |
| Net Cash from Operations | ($0.16B) | ($0.10B) | ($0.09B) | ($0.10B) | ($0.08B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.24B) | ($0.20B) | ($0.12B) | ($0.18B) | ($0.14B) |
| Sales of Investments | $0.18B | $0.19B | $0.13B | $0.21B | $0.05B |
| Net Cash from Investing | ($0.06B) | ($0.02B) | $0.01B | $0.06B | ($0.09B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | ($0.01B) | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.00B) | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.19B | $0.12B | $0.00B | $0.07B | $0.13B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.16B) | ($0.10B) | ($0.10B) | ($0.10B) | ($0.08B) |
| FCF Margin %(computed) | — | — | — | — | -580.36% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Solid Biosciences Inc. data
About Solid Biosciences Inc. (SLDB) Cash Flow Statement
Solid Biosciences Inc. generated operating cash flow of ($0.16B) and free cash flow of ($0.16B) for 2025 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
SLDB · 4 questionsSolid Biosciences Inc. generated free cash flow of ($0.16B) for 2025, down 56.4% year-over-year.
SLDB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10